Arthroscopic Matrix-Encapsulated Autologous Chondrocyte Implantation : A Pilot Multicenter Investigation in Latin America
Objective. To evaluate minimum biosecurity parameters (MBP) for arthroscopic matrix-encapsulated autologous chondrocyte implantation (AMECI) based on patients' clinical outcomes, magnetic resonance imaging (MRI) T2-mapping, Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score, and International Cartilage Repair Society (ICRS) second-look arthroscopic evaluation, laying the basis for a future multicenter study. Design. Pilot clinical study. We analyzed the logistics to perform AMECI to treat focal chondral lesions in different hospitals following strict biosecurity parameters related to tissue and construct transportation, chondrocyte isolation, and cell expansion. Patient progress was analyzed with patient-reported outcome measures, MRI T2-mapping, MOCART, and ICRS arthroscopic second-look evaluation. Results. Thirty-five lesions in 30 patients treated in 7 different hospitals were evaluated. Cell viability before implantation was >90%. Cell viability in construct remnants was 87% ± 11% at 24 hours, 75% ± 17.1% at 48 hours, and 60% ± 8% at 72 hours after implantation. Mean final follow-up was 37 months (12-72 months). Patients showed statistically significant improvement in all clinical scores and MOCART evaluations. MRI T2-mapping evaluation showed significant decrease in relaxation time from 61.2 ± 14.3 to 42.9 ± 7.2 ms (P < 0.05). Arthroscopic second-look evaluation showed grade II "near normal" tissue in 83% of patients. Two treatment failures were documented. Conclusions. It was feasible to perform AMECI in 7 different institutions in a large metropolitan area following our biosecurity measures without any implant-related complication. Treated patients showed improvement in clinical, MRI T2-mapping, and MOCART scores, as well as a low failure rate and a favorable ICRS arthroscopic evaluation at a mid-term follow-up. Level of Evidence. 2b.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cartilage - 13(2021), 1_suppl vom: 10. Dez., Seite 1074S-1084S |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Villalobos, Enrique [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AMECI |
|---|
| Anmerkungen: |
Date Completed 06.04.2022 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1947603520918630 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30989106X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30989106X | ||
| 003 | DE-627 | ||
| 005 | 20231225134912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1947603520918630 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM30989106X | ||
| 035 | |a (NLM)32406246 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Villalobos, Enrique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arthroscopic Matrix-Encapsulated Autologous Chondrocyte Implantation |b A Pilot Multicenter Investigation in Latin America |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective. To evaluate minimum biosecurity parameters (MBP) for arthroscopic matrix-encapsulated autologous chondrocyte implantation (AMECI) based on patients' clinical outcomes, magnetic resonance imaging (MRI) T2-mapping, Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score, and International Cartilage Repair Society (ICRS) second-look arthroscopic evaluation, laying the basis for a future multicenter study. Design. Pilot clinical study. We analyzed the logistics to perform AMECI to treat focal chondral lesions in different hospitals following strict biosecurity parameters related to tissue and construct transportation, chondrocyte isolation, and cell expansion. Patient progress was analyzed with patient-reported outcome measures, MRI T2-mapping, MOCART, and ICRS arthroscopic second-look evaluation. Results. Thirty-five lesions in 30 patients treated in 7 different hospitals were evaluated. Cell viability before implantation was >90%. Cell viability in construct remnants was 87% ± 11% at 24 hours, 75% ± 17.1% at 48 hours, and 60% ± 8% at 72 hours after implantation. Mean final follow-up was 37 months (12-72 months). Patients showed statistically significant improvement in all clinical scores and MOCART evaluations. MRI T2-mapping evaluation showed significant decrease in relaxation time from 61.2 ± 14.3 to 42.9 ± 7.2 ms (P < 0.05). Arthroscopic second-look evaluation showed grade II "near normal" tissue in 83% of patients. Two treatment failures were documented. Conclusions. It was feasible to perform AMECI in 7 different institutions in a large metropolitan area following our biosecurity measures without any implant-related complication. Treated patients showed improvement in clinical, MRI T2-mapping, and MOCART scores, as well as a low failure rate and a favorable ICRS arthroscopic evaluation at a mid-term follow-up. Level of Evidence. 2b | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AMECI | |
| 650 | 4 | |a T2-mapping | |
| 650 | 4 | |a biosecurity parameters | |
| 650 | 4 | |a matrix-assisted autologous chondrocyte implantation | |
| 650 | 4 | |a multicenter study | |
| 700 | 1 | |a Madrazo-Ibarra, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Valentín |e verfasserin |4 aut | |
| 700 | 1 | |a Olivos-Meza, Anell |e verfasserin |4 aut | |
| 700 | 1 | |a Velasquillo, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cortés González, Socorro |e verfasserin |4 aut | |
| 700 | 1 | |a Izaguirre, Aldo |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Sánchez, Carmina |e verfasserin |4 aut | |
| 700 | 1 | |a González, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Parra-Cid, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Jiménez, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Ibarra, Clemente |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cartilage |d 2010 |g 13(2021), 1_suppl vom: 10. Dez., Seite 1074S-1084S |w (DE-627)NLM199891206 |x 1947-6043 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1_suppl |g day:10 |g month:12 |g pages:1074S-1084S |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1947603520918630 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 1_suppl |b 10 |c 12 |h 1074S-1084S | ||